|
Price: $75.8100
$-0.48 
-0.629%
|
| Day's High:
| $75.83999633789062
| Week Perf:
| -1.67 %
|
| Day's Low: |
$ 74.83 |
30 Day Perf: |
-1.89 % |
| Volume (M): |
4,169,500 |
52 Wk High: |
$ 152.97 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$110.65 |
| Open: |
$75.08 |
52 Wk Low: |
$71.00 |
|
|
| Market Capitalization (Millions $) |
31,666 |
| Shares
Outstanding (Millions) |
418 |
| Employees |
14,500 |
| Revenues (TTM) (Millions $) |
9,517 |
| Net Income (TTM) (Millions $) |
2,616 |
| Cash Flow (TTM) (Millions $) |
368 |
| Capital Exp. (TTM) (Millions $) |
404 |
Business Description
Zoetis Inc. is a prominent player in the animal health industry, recognized for its global reach and comprehensive range of products and services tailored to meet the needs of animal owners, veterinarians, and farmers. The company is dedicated to enhancing the health and well-being of a variety of animals and actively seeks to provide sustainable, integrated solutions for animal healthcare.
Founded in 1952 as a division of Pfizer Inc. Zoetis became an independent entity through an initial public offering (IPO) in 2013. Headquartered in Parsippany, New Jersey, the company has expanded its workforce to nearly 10,000 employees and has established a presence in more than 100 countries around the world.
Zoetis’s extensive product portfolio includes vaccines, parasiticides, anti-infectives, and other pharmaceuticals designed for livestock, poultry, companion animals, and aquaculture. Furthermore, the company offers diagnostic products and services, genetic testing, and a variety of digital health tools that support veterinary professionals in delivering informed care to animals.
The company operates through four primary business segments:
1. United States - This segment represents Zoetiss largest market and encompasses a wide range of products for the care of dogs, cats, horses, and livestock.
2. International - This segment provides animal health products and services to customers across various regions outside of the United States.
3. Cattle - Focused on the health and wellness of cattle, this segment offers preventative and therapeutic products for various diseases and parasites.
4. Other - This segment includes offerings related to aquaculture and other animal species not covered in the core segments.
Zoetis engages in the manufacture and distribution of its products through a network of distributors, veterinarians, and animal healthcare professionals. The company places a significant emphasis on research and development, making substantial investments to enhance existing products and develop new ones. Its robust pipeline of innovations is supported by partnerships with leading research institutions, underscoring its commitment to ongoing advancement in the field of animal health.
In addition to its focus on animal health, Zoetis prioritizes corporate social responsibility through various initiatives. These efforts include sustainability practices aimed at mitigating the environmental impact of its operations, promoting employee volunteer activities, and fostering collaborations with organizations that champion animal health and welfare.
Overall, Zoetis Inc. stands as a global leader in animal health, providing a diverse portfolio of products and digital solutions while promoting sustainable practices and community support efforts.
Company Address: 10 Sylvan Way, Parsippany, 7054 NJ
Company Phone Number: 822-7000 Stock Exchange / Ticker: NYSE ZTS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Mon, Nov 4 2024 12:08 PM UTC
Zoetis Inc.: A Beacon of Growth in Animal Health and Commitment to DiversityAs the global landscape of animal health continues to evolve, Zoetis Inc. (NYSE: ZTS) has been at the forefront, exhibiting remarkable financial growth and an unwavering commitment to Diversity, Equity, and Inclusion (DE&I). With significant strides made in the third quarter of 2024, alongside recog...
|
| Business Update
Published Tue, Aug 6 2024 11:56 AM UTC
: Zoetis Inc., a leading global animal health company, has disclosed its financial performance for the second quarter of 2024, showcasing significant growth in revenue and net income. The positive trends prompted an upward revision of its financial guidance for the full year. On July 30, 2024, Zoetis Inc. (NYSE: ZTS) announced its financial results for the second quarter of...
|
| Dividend
Published Thu, May 23 2024 10:08 AM UTC
Zoetis Inc., the leading animal health company, has recently announced the declaration of a $0.432 per share dividend for the third quarter of 2024. This news comes as a testament to Zoetis dedication to nurturing the world and advancing care for animals. The dividend is scheduled to be paid on September 4, 2024, to all shareholders of record as of July 18, 2024.
Z...
|
| Business Update
Published Tue, May 14 2024 7:47 PM UTC
Zoetis: Leading the Pack in Animal Health and Diversity ExcellenceZoetis Inc. (NYSE: ZTS), a global leader in animal health, has garnered a prestigious accolade by being named to Fair360 s Top 50 Companies for Diversity, Equity, and Inclusion (DE&I) for the first time. This recognition emphasizes the company s unwavering dedication and continuous strides in promoting a dive...
|
| Business Update
Published Thu, May 2 2024 11:47 AM UTC
In a recent announcement, Zoetis Inc., a leading global animal health company, shared its financial results for the first quarter of 2024. The company celebrated a remarkable revenue growth of 10% compared to the same period in 2023, showcasing its strong market performance and strategic initiatives. This article aims to examine the key facts and assess their implications on...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
6.12 $ |
| Revenues (TTM) |
22.78 $
|
| Cash Flow (TTM) |
0.88 $ |
| Cash |
4.01 $
|
| Book Value |
7.54 $
|
| Dividend (TTM) |
2.09 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
656,345 |
| Net
Income per Employee (TTM) |
180,414 |
| Receivable Turnover Ratio (TTM) |
6.13 |
| Inventory Turnover Ratio (TTM) |
1.08 |
| Asset Turnover Ratio (TTM) |
0.63 |
|
|
| Per Share |
|
| Earnings (TTM) |
6.12 $
|
| Revenues (TTM) |
22.78 $ |
| Cash Flow (TTM) |
0.88 $ |
| Cash |
4.01 $
|
| Book Value |
7.54 $ |
| Dividend (TTM) |
2.09 $ |
|
|
| |
| United States |
|
 95.46 % |
of total Revenue |
| Australia |
|
7.41 % |
of total Revenue |
| Brazil |
|
7.82 % |
of total Revenue |
| Canada |
|
5.88 % |
of total Revenue |
| Chile |
|
2.92 % |
of total Revenue |
| China |
|
5.06 % |
of total Revenue |
| France |
|
3.12 % |
of total Revenue |
| Germany |
|
5.19 % |
of total Revenue |
| Italy |
|
3.2 % |
of total Revenue |
| Horses |
|
6.08 % |
of total Revenue |
| Mexico |
|
3.85 % |
of total Revenue |
| Spain |
|
3.36 % |
of total Revenue |
| United Kingdom |
|
6.08 % |
of total Revenue |
| Other developed markets |
|
14.42 % |
of total Revenue |
| Other emerging markets |
|
22.69 % |
of total Revenue |
| Total geographical area |
|
189.55 % |
of total Revenue |
| Contract Manufacturing and Human Health Diagnostics |
|
2.11 % |
of total Revenue |
| International |
|
94.08 % |
of total Revenue |
| Companion Animal |
|
130.75 % |
of total Revenue |
| Livestock |
|
58.79 % |
of total Revenue |
| Dogs and Cats |
|
124.68 % |
of total Revenue |
| Cattle |
|
31.69 % |
of total Revenue |
| Swine |
|
9.72 % |
of total Revenue |
| Poultry |
|
9.44 % |
of total Revenue |
| Fish |
|
6.04 % |
of total Revenue |
| Manufactured Product, Other |
|
1.9 % |
of total Revenue |
| Parasiticides |
|
52.03 % |
of total Revenue |
| Vaccines |
|
42.14 % |
of total Revenue |
| Dermatology |
|
30.27 % |
of total Revenue |
| Anti-infective Products |
|
19.65 % |
of total Revenue |
| Pain & Sedation |
|
17.02 % |
of total Revenue |
| Other pharmaceuticals |
|
13.21 % |
of total Revenue |
| Animal health diagnostics |
|
9.72 % |
of total Revenue |
| Other Non Pharmaceuticals |
|
5.51 % |
of total Revenue |
| Total products and services |
|
189.55 % |
of total Revenue |
| |
On February 13 2025 the Zoetis Inc provided following guidance
nnZoetis Inc. Financial Results and Guidance Update for 2025nn
PARSIPPANY, N.J. - Zoetis Inc. (NYSE: ZTS), a leader in animal health, has announced its financial performance for the fourth quarter and the entire fiscal year 2024. Alongside these results, the company has also shared its guidance for the upcoming fiscal year of 2025.
For the fourth quarter of 2024, Zoetis achieved a robust revenue total of $2.3 billion, marking a 5% increase in comparison to the same period in 2023. On an operational basis, which accounts for currency fluctuations and other factors, the revenue growth was even more significant, rising by 6% year-over-year.
The net income for the fourth quarter reache...
|
|
|
1.62% 